AURORA, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- Losing weight can often feel like an uphill battle, with conflicting advice and complicated diets making the process overwhelming. However, a simple yet effective method has been gaining traction in weight loss—the Ice Water Hack. When combined with Aqua Sculpt, a cutting-edge thermogenic formula, this straightforward technique can be a helpful addition to a balanced diet and regular exercise routine. It amplifies the body's fat-burning capabilities through ...

Core Concept - The Ice Water Hack, developed by Dr. Blaine, is a weight-loss strategy that activates metabolism through a simple morning routine involving ice-cold water and a specialized capsule, promoting sustained fat-burning throughout the day [1][9][34]. Group 1: Mechanism and Benefits - The Ice Water Hack combines cold water with a proprietary formula called Aqua Sculpt, which includes botanicals and amino acids that enhance thermogenesis, allowing the body to burn fat more effectively [3][12][26]. - Users report significant weight loss, with testimonials indicating losses of 30-40 pounds in a few weeks, and an average of 27.8 pounds lost in a pilot study with over 1,000 participants [2][50]. - The method claims to increase fat burning by 720% to over 1,000% compared to cold water alone, providing a continuous metabolic boost [13][21]. Group 2: Ingredients and Their Roles - Aqua Sculpt contains key ingredients such as Chlorogenic Acid, L-Carnitine, EGCG, Chromium, and L-Theanine, each contributing to enhanced fat metabolism and energy levels [17][21][22][23][24]. - These ingredients work synergistically to prolong the thermogenic effect initiated by cold water, ensuring that the metabolism remains active for extended periods [26][27]. Group 3: User Experience and Lifestyle Integration - The Ice Water Hack is designed for easy integration into daily routines, requiring only a 7-second commitment each morning, making it accessible for individuals with busy lifestyles [6][48]. - Users have reported not only weight loss but also improved energy levels, better mood, and enhanced overall well-being, indicating a holistic benefit beyond just fat loss [29][32][33]. Group 4: Scientific Backing and Research - Preliminary studies from institutions like Harvard and Stanford support the concept that cold exposure can boost metabolic rates, while additional research indicates that specific compounds can extend fat oxidation significantly [7][8]. - Dr. Blaine's research emphasizes the importance of maintaining an active metabolism throughout the day, which the Ice Water Hack aims to achieve [10][39].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from to . Commission File Number: 333-82900 ThermoGenesis Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State of incorporation) 94 ...

Table of Contents Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $.001 par value THMO Nasdaq Capital Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to THERMOGENESIS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware (State of incorporation) 94-3018487 (I.R.S. Employer Ide ...

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications, IR Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day. And welcome to the ThermoGenesis Holdings Conference Call and Webcast to Review Financial and Operating Results for the Third Quarter ended September 30, 2023. As a reminder, this call is being r ...

Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________. Commission File Number: 333-82900 ThermoGenesis Holdings, Inc. (Exact name of registrant as specified in its charter) De ...

Thermogenesis Holdings, Inc. (NASDAQ:THMO) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Paula Schwartz - IR, Rx Communications Group Chris Xu - CEO Jeff Cauble - CFO Conference Call Participants Sean Lee - H.C. Wainwright & Co. Operator Good day, and welcome to the ThermoGenesis Holdings conference call and webcast to review financial and operating results for the second quarter ended June 30, 2023. [Operator Instructions]. As a reminder, this conference call is being rec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________. Commission File Number: 333-82900 Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading ...

ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to review Financial and Operating Results for the First Quarter ended March 31, 2023. [Operator Instructions] As a reminder, this conferen ...

Financial Performance - Net revenues decreased by $91,000 or 3%, from $2,663,000 to $2,572,000 for the three months ended March 31, 2023, compared to the same period in 2022[79]. - Gross profit increased by $165,000 to $1,105,000, representing 43% of net revenues for the three months ended March 31, 2023, up from 35% in the prior year[81]. - Selling, general and administrative expenses rose by $151,000 or 9%, totaling $1,844,000 for the three months ended March 31, 2023, driven by CDMO facility expenses[82]. - Research and development expenses decreased by $150,000 or 33%, amounting to $306,000 for the three months ended March 31, 2023[83]. - Interest expense surged by $3,080,000 to $3,903,000 for the three months ended March 31, 2023, primarily due to additional amortization expenses related to convertible notes[84]. Cash Position - Cash and cash equivalents increased to $5,854,000 as of March 31, 2023, compared to $4,177,000 at December 31, 2022[86]. Capital and Funding - The company raised approximately $2.6 million through a private placement of common stock and warrants on March 20, 2023[87]. - The company anticipates needing additional capital to fund operations and grow its business, raising concerns about its ability to continue as a going concern[88]. Business Development - The company plans to complete its new CDMO facility in 2023, which will include 12 class-7, ReadyStart cGMP Suites[75]. - The company is developing a proprietary manufacturing platform for cell manufacturing activities as part of its CDMO business expansion[74].